natgillin/translations-raw huggingface dataset:
ildenafil, vardenafil eller tadalafil (anvendes af mænd til at behandle impotens (erektil dysfunktion)) hvis du tager p-piller samtidig med REYATAZ for at undgå graviditet, er det vigtigt, at du tager dem nøjagtigt som lægen har fortalt dig, og at du ikke glemmer en dosis medicin, der bruges til at behandle sygdomme, der er forbundet med indholdet af syre i maven (f.eks. antacida (syreneutraliserende), der tages 1 time før REYATAZ eller 2 timer efter REYATAZ, H2-hæmmere som f.eks. famotidin og protonpumpehæmmere som f.eks. omeprazol)
ildenafil, vardenafil, or tadalafil (used by men to treat impotence (erectile dysfunction)) if you are taking an oral contraceptive ("the Pill") with REYATAZ to prevent pregnancy, be sure to take it exactly as instructed by your doctor and not miss any doses any medicines used to treat diseases related to the acid in the stomach (e.g. antacids to be taken 1 hour before taking REYATAZ or 2 hours after taking REYATAZ, H2-blockers like famotidine and proton pump inhibitors like omeprazole)
ildenafil, vardenafil eller tadalafil (mod impotens)
ildenafil, vardenafil or tadalafil (used to treat erectile dysfunction)
ildenafil, vardenafil, tadalafil (mod impotens eller for højt blodtryk i lungekredsløbet)
Sildenafil, vardenafil, tadalafil (for erectile dysfunction or high blood pressure in the pulmonary circulation)
ildenafil, vardenafil, tadalafil – anvendes mod impotens
ildenafil, vardenafil, tadalafil - used for impotence
Ildere
Ferrets
Ildere bør behandles i starten af avlssæsonen.
Treatment in ferrets should be initiated at the beginning of the breeding season.
Ildere: Der er ikke tilgængelig information for ildere.
Ferrets: There is no information available in ferrets.
Ileus
Odynophagia
Ileus/intestinal obstruktion*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)*
Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)
ILF er en kronisk fibrotisk og inflammatorisk lungesygdom, som påvirkes af syntese og frigivelse af proinflammatoriske cytokiner, herunder tumornekrosefaktor alfa (TNF-α) og interleukin-1-beta (IL- 1β), og pirfenidon er vist at reducere akkumulation af inflammatoriske celler som reaktion på forskellige stimuli.
IPF is a chronic fibrotic and inflammatory pulmonary disease affected by the synthesis and release of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-α) and interleukin-1-beta (IL-1β) and pirfenidone has been shown to reduce the accumulation of inflammatory cells in response to various stimuli.
ILF er en sygdom, hvor vævet i lungerne hæver og bliver arret over tid, og det gør det svært at trække vejret dybt.
IPF is a condition in which the tissues in your lungs become swollen and scarred over time, and as a result makes it difficult to breathe deeply.
ilica, kolloid vandfri jernoxid mannitol aspartam (E951) tutti-frutti aroma
colloidal silicon dioxide ferric oxide mannitol aspartame (E951) flavour Tutti-Frutti
ilikoneklæbestof diethylenglycolmonoethylether siliconeolie ethylcellulose N50 (E462)
diethylene glycol monoethyl ether silicone oil ethylcellulose N50 (E462)
ilikoneklæbestof diethylenglycolmonoethylether silikoneolie ethylcellulose N50 (E462)
diethylene glycol monoethyl ether silicone oil ethylcellulose N50 (E462)
ilikoneolie dimethicon
ilicone oil, dimethicone.
illusioner), mareridte,
hallucination
Illustration (piktogram) af intravitreal injektionsprocedure
Intravitreal injection procedure pictogram
iltforsyningen til milten er afbrudt (miltinfarkt) – dette kan give svære mavesmerter
oxygen supply to the spleen is interrupted (splenic infarction) - this may cause severe stomach pain
iltmangel
oxygen deficiency
Ilæggelse af en kapsel:
Insert capsule:
IM
I.M.
IM.
IM
Imatinib 400 mg
Imatinib
Imatinib 400 mg 1 gang dagligt (n = 283) Ved 6 år
Imatinib 400 mg once daily (n = 283) By 6 years
Imatinib Accord 100 mg filmovertrukne tabletter er brun-orange, runde, bikonvekse filmovertrukne tabletter, præget med ‘IM’ og ‘T1’ på hver sin side af delekærven på den ene side, jævne på den anden side.
Imatinib Accord 100 mg film-coated tablets are brownish orange, round biconvex, film-coated tablets, debossed on one side with ‘IM’ and ‘T1’ on either side of breakline and plain on the other side.
Imatinib Accord 100 mg filmovertrukne tabletter Imatinib
Imatinib Accord 100 mg film-coated tablets Imatinib
Imatinib Accord 100 mg filmovertrukne tabletter Imatinib Accord 400 mg filmovertrukne tabletter Imatinib
Imatinib Accord 100mg film-coated tablets Imatinib Accord 400mg film-coated tablets Imatinib
Imatinib Accord 100 mg filmovertrukne tabletter:
Imatinib Accord 100 mg film-coated tablets:
Imatinib Accord 400 mg filmovertrukne tabletter er brun-orange, ovale, bikonvekse filmovertrukne tabletter, præget med ‘IM’ og ‘T2’ på hver sin side af delekærven på den ene side, jævne på den anden.
Imatinib Accord 400 mg film-coated tablets are brownish orange, oval shaped, biconvex, film-coated tablets, debossed on one side with ‘IM’ and ‘T2’ on either side of breakline and plain on the other side.
Imatinib Accord 400 mg filmovertrukne tabletter Imatinib
Imatinib Accord 400 mg film-coated tablets Imatinib
Imatinib Accord 400 mg filmovertrukne tabletter:
Imatinib Accord 400 mg film-coated tablets:
Imatinib Accord anbefales ikke under graviditeten, medmindre det er strengt nødvendigt, da det kan skade din baby.
Imatinib Accord is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Imatinib Accord anvendes hos børn, som for nylig har fået diagnosticeret Ph+ CML, og som ikke egner sig til en knoglemarvstransplantation.
Imatinib Accord is used in children who have been newly diagnosed with Ph+ CML and who are not eligible for a bone marrow transplant.
Imatinib Accord anvendes i kombination med andre lægemidler mod kræft til voksne, som for nylig har fået diagnosticeret Ph+ ALL.
Imatinib Accord is used in combination with other anticancer medicines in adults who have been newly diagnosed with Ph+ ALL.
Imatinib Accord anvendes også hos voksne med Ph+ CML i blastkrise.
It is also used in adults with Ph+ CML in blast crisis;
Imatinib Accord anvendes til behandling af voksne med DFSP, som ikke kan fjernes kirurgisk, og til voksne, som ikke egner sig til et kirurgisk indgreb, når der er tilbagefald af kræften efter behandling, eller når den har spredt sig til andre dele af kroppen.
Imatinib Accord is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.
Imatinib Accord anvendes til behandling af voksne med HES eller CEL, hos hvem der forekommer en særlig omarrangering af de to gener FIP1L1 og PDGFRα dermatofibrosarcoma protuberans (DFSP), en form for kræft (sarkom), hvor cellerne i vævet under huden begynder at dele sig ukontrolleret.
Imatinib Accord is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Imatinib Accord anvendes til behandling af voksne med MD/MPD, hos hvem genet for blodpladederiveret vækstfaktorreceptor (PDGFR) har omarrangeret sig fremskredent hypereosinofilt syndrom (HES) eller kronisk eosinofil leukæmi (CEL), som er sygdomme, hvor eosinofiler (en anden form for hvide blodlegemer) begynder at vokse ukontrolleret.
MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR); advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Imatinib Accord anvendes, når patienten er "Philadelphiakromosompositiv" (Ph+).
Imatinib Accord is used when the patients are ‘Philadelphia chromosome positive’ (Ph+).
Imatinib Accord bruges også til behandling af børn med CML.
Imatinib Accord is also a treatment for children with CML.
Imatinib Accord er et "generisk lægemiddel".
Imatinib Accord is a ‘generic medicine’.
Imatinib Accord er et lægemiddel mod kræft, som indeholder det aktive stof imatinib.
Imatinib Accord is an anticancer medicine that contains the active substance imatinib.
Imatinib Accord er indiceret til behandling af børn med nydiagnosticeret Philadelphiakromosom (bcr-abl) positiv (Ph+) kronisk myeloid leukæmi (CML), for hvilke knoglemarvstransplantation ikke anses for førstevalgsbehandling. børn med Ph+ CML i kronisk fase efter manglende effekt af alfa-interferonbehandling, eller i accelereret fase eller blastkrise. voksne patienter med Ph+ CML i blastkrise. voksne patienter med nydiagnosticeret Philadelphiakromosom positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD) som er forbundet med platelet-derived growth factor receptor-omlejring (PDGFR-omlejring). voksne patienter med refraktært hypereosiniphil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL) uden FIP1L1-PDGFR-omlejring. voksne patienter med inoperabel dermatofibrosarkom protuberans (DFSP) og voksne patienter med residiverende og/eller metastaserende DFSP som ikke er tilgængelig for kirurgi.
Imatinib Accord is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adults patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Imatinib Accord fås som tabletter (100 og 400 mg).
Imatinib Accord is available as tablets (100 and 400 mg).
Imatinib Accord gives oralt sammen med et måltid og et stort glas vand for at mindske risikoen for irritation af mave-tarm-kanalen.
Imatinib Accord is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
Imatinib Accord hæmmer væksten af disse blodlegemer i en vis undergruppe af disse sygdomme.
Imatinib Accord inhibits the growth of these cells in a certain subtype of these diseases.
Imatinib Accord kan føre til, at din krop kan begynde at ophobe væske (svære ødemer).
Imatinib Accord may cause your body to retain water (severe fluid retention).
Imatinib Actavis 100 mg filmovertrukne tabletter
Imatinib Actavis 100 mg film-coated tablets
Imatinib Actavis 400 mg filmovertrukne tabletter
Imatinib Actavis 400 mg film-coated tablets
Imatinib Actavis 50 mg hårde kapsler
Imatinib Actavis 50 mg hard capsules
Imatinib Actavis anbefales ikke under graviditeten, medmindre det er strengt nødvendigt, da det kan skade din baby.
Imatinib Actavis is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Imatinib Actavis anvendes i kombination med andre lægemidler mod kræft til voksne, som for nylig har fået diagnosticeret Ph+ ALL.
Imatinib Actavis is used in combination with other anticancer medicines in adults who have been newly diagnosed with Ph+ ALL.
Imatinib Actavis anvendes også hos voksne med Ph+ CML i blastkrise
Imatinib Actavis is also used in adults with Ph+ CML in blast crisis.
Imatinib Actavis anvendes også til behandling af voksne med:
Imatinib Actavis is also a treatment for adults for:
Imatinib Actavis anvendes til behandling af voksne med DFSP, som ikke kan fjernes kirurgisk, og til voksne, som ikke egner sig til et kirurgisk indgreb, når der er tilbagefald af kræften efter behandling, eller når den har spredt sig til andre dele af kroppen.
Imatinib Actavis is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.
Imatinib Actavis anvendes til behandling af voksne med HES eller CEL, hos hvem der forekommer en særlig omarrangering af de to gener FIP1L1 og PDGFRα dermatofibrosarcoma protuberans (DFSP), en form for kræft (sarkom), hvor cellerne i vævet under huden begynder at dele sig ukontrolleret.
Imatinib Actavis is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα; dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Imatinib Actavis anvendes til behandling af voksne med MD/MPD, hos hvem genet for blodpladederiveret vækstfaktorreceptor (PDGFR) har omarrangeret sig fremskredent hypereosinofilt syndrom (HES) eller kronisk eosinofil leukæmi (CEL), som er sygdomme, hvor eosinofiler (en anden form for hvide blodlegemer) begynder at vokse ukontrolleret.
MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR); advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Imatinib Actavis anvendes, når patienten er »Philadelphiakromosompositiv« (Ph+).
Imatinib Actavis is used when the patients are ‘Philadelphia-chromosome positive’ (Ph+).
Imatinib Actavis bruges også til behandling af børn og teenagere med CML.
Imatinib Actavis is also a treatment for children and adolescents with CML.
Imatinib Actavis bruges også til behandling af børn og unge med CML.
Imatinib Actavis is also a treatment for children and adolescents with CML.
Imatinib Actavis er et lægemiddel mod kræft, som indeholder det aktive stof imatinib.
Imatinib Actavis is an anticancer medicine that contains the active substance imatinib.
Imatinib Actavis er et »generisk lægemiddel«.
Imatinib Actavis is a ‘generic medicine’.
Imatinib Actavis er indiceret til behandling af børn med nydiagnosticeret Philadelphiakromosom (bcr-abl) positiv (Ph+) kronisk myeloid leukæmi (CML), for hvilke knoglemarvstransplantation ikke anses for førstevalgsbehandling. børn med Ph+ CML i kronisk fase efter manglende effekt af alfa-interferonbehandling, eller i accelereret fase eller blastkrise. voksne med Ph+ CML i blastkrise. voksne med nydiagnosticeret Philadelphia-kromosom-positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD) som er forbundet med platelet-derived growth factor receptor-omlejring (PDGFR-omlejring). voksne patienter med refraktært hypereosiniphil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL) uden FIP1L1- PDGFRα-omlejring.
Imatinib Actavis is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Imatinib Actavis er indiceret til behandling af børn med nydiagnosticeret Philadelphiakromosom (bcr-abl) positiv (Ph+) kronisk myeloid leukæmi (CML), for hvilke knoglemarvstransplantation ikke anses for førstevalgsbehandling. børn med Ph+ CML i kronisk fase efter manglende effekt af alfa-interferonbehandling, eller i accelereret fase eller blastkrise. voksne med Ph+ CML i blastkrise. voksne med nydiagnosticeret Philadelphia-kromosom-positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD) som er forbundet med platelet-derived growth factor receptor-omlejring (PDGFR-omlejring). voksne patienter med refraktært hypereosiniphil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL) uden FIP1L1-PDGFR-omlejring.
Imatinib Actavis is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Imatinib Actavis er indiceret til behandling af børn med nydiagnosticeret Philadelphiakromosom (bcr-abl) positiv (Ph+) kronisk myeloid leukæmi (CML), for hvilke knoglemarvstransplantation ikke anses for førstevalgsbehandling.- børn med Ph+ CML i kronisk fase efter manglende effekt af alfa-interferonbehandling, eller i accelereret fase eller blastkrise. voksne med Ph+ CML i blastkrise. voksne med nydiagnosticeret Philadelphia-kromosom-positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD) som er forbundet med platelet-derived growth factor receptor-omlejring (PDGFR-omlejring). voksne patienter med refraktært hypereosiniphil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL) uden FIP1L1-PDGFR-omlejring.
Imatinib Actavis is indicated for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with Ph+ CML in blast crisis. adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
Imatinib Actavis er indiceret til behandling af voksne patienter med inoperabel dermatofibrosarkom protuberans (DFSP) og voksne patienter med residiverende og/eller metastaserende DFSP som ikke er tilgængelig for kirurgi.
Imatinib Actavis is indicated for the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Imatinib Actavis fås som kapsler (50, 100 og 400 mg) og tabletter (100 og 400 mg).
Imatinib Actavis is available as capsules (50, 100 and 400 mg) and tablets (100 and 400 mg).
Imatinib Actavis gives oralt sammen med et måltid og et stort glas vand for at mindske risikoen for irritation af mave-tarm-kanalen.
Imatinib Actavis is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
Imatinib Actavis hæmmer væksten af disse blodlegemer i en vis undergruppe af disse sygdomme.
Imatinib Actavis inhibits the growth of these cells in a certain subtype of these diseases.
Imatinib ansås ikke som værende genotoksisk i in vitro bakteriecelleundersøgelse (Ames test), i in-vitro pattedyrscelleundersøgelse (muselymfom) samt i in vivo rottemikronukleusundersøgelse.
Imatinib was not considered genotoxic when tested in an in vitro bacterial cell assay (Ames test), an in vitro mammalian cell assay (mouse lymphoma) and an in vivo rat micronucleus test.
Imatinib blev administreret periodisk i kohorte 1-5 med stigende varighed og tidligere start med imatinib fra kohorte til kohorte; kohorte 1 fik den mindst intensive imatinibbehandling og kohorte 5 den mest intensive (længste varighed i dage med kontinuerlig, daglig imatinibdosering i de første kemobehandlingsforløb).
1-5, with increasing duration and earlier start of imatinib from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of imatinib (longest duration in days with continuous daily imatinib dosing during the first chemotherapy treatment courses).
Imatinib farmakokinetik er evalueret i dosisintervallet: 25–1.000 mg.
The pharmacokinetics of imatinib have been evaluated over a dosage range of 25 to 1,000 mg.
Imatinib hæmmer også receptortyrosinkinaserne for trombocytafledte vækstfaktorer (PDGF), PDGF- R og PDGF-medierede cellulære signaler.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF-mediated cellular events.
Imatinib hæmmer også receptortyrosinkinaserne for trombocytafledte vækstfaktorer (PDGF), PDGF- R og PDGF-medierede cellulære signaler.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF),PDGF-R, and inhibits PDGF-mediated cellular events.
Imatinib hæmmer også receptortyrosinkinaserne for trombocytafledte vækstfaktorer (PDGF), PDGF- R, og hæmmer PDGF-medierede cellulære signaler.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF- mediated cellular events.
Imatinib hæmmer også receptortyrosinkinaserne for trombocytafledte vækstfaktorer (PDGF), PDGF- R, og stamcellefaktorer (SCF), c-Kit, og hæmmer PDGF- og SCF-medierede cellulære signaler.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events.
Imatinib kan øge plasmakoncentrationen af andre CYP3A4-metaboliserede lægemidler (for eksempel triazol-benzodiazepiner, dihydropyridin-calciumantagonister, visse HMG- CoA reduktasehæmmere, såsom statiner osv.).
Imatinib may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.).